IND Application for Simcere’s Independently Developed Anti-TNFR2 Antibody Accepted by CDE

Envafolimab in Combination with Lenvatinib for the Treatment of Endometrial Cancer Granted Implied License for Clinical Trials

Latest Study Data of Sanbexin^® Released at ESOC 2021

Simcere Pharmaceutical Group Announces 2021 Interim Results | Solid Revenue Growth Driven by Sanbexin^®, and Rapid Progress in Innovative R&D

Trilaciclib Granted Fast Track Designation by the U.S. FDA for Use in Combination with Chemotherapy for the Treatment of TNBC

Phase Ⅱ Clinical Data of Envafolimab in MSI-H/dMMR Solid Tumors Published in the Journal of Hematology & Oncolog

Envafolimab Obtained Its 2nd Orphan Drug Designation from the U.S. Food and Drug Administration

Simcere and Vivoryon Therapeutics Announce Strategic Regional Licensing Partnership for N3pE Amyloid-Targeting Medicines to Treat Alzheimer’s Disease in Greater China

Iremod ^® (Iguratimod Tablets) Press Conference on Phase IV Clinical Study Results Held in Beijing

Simcere Announces the Approval of Clinical Trial Application by NMPA to Initiate China Phase Ⅲ Study Sites for the Global Clinical Trial of Trilaciclib in the Treatment of Triple-Negative Breast Cancer (TNBC)